Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus.

Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Ioannidis JP.

Rheumatology (Oxford). 2002 Jul;41(7):780-6.

PMID:
12096228
2.
3.

Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.

Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM.

J Rheumatol. 2002 Oct;29(10):2129-35.

PMID:
12375322
4.

Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.

Pryor BD, Bologna SG, Kahl LE.

Arthritis Rheum. 1996 Sep;39(9):1475-82. Erratum in: Arthritis Rheum 1997 Sep;40(9):1711.

PMID:
8814058
5.

Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy.

Opastirakul S, Chartapisak W.

Pediatr Nephrol. 2005 Dec;20(12):1750-5. Epub 2005 Aug 24.

PMID:
16133037
6.

Moderate and severe neutropenia in patients with systemic lupus erythematosus.

Martínez-Baños D, Crispín JC, Lazo-Langner A, Sánchez-Guerrero J.

Rheumatology (Oxford). 2006 Aug;45(8):994-8. Epub 2006 Feb 16.

PMID:
16484291
7.

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.

Petri M, Jones RJ, Brodsky RA.

Arthritis Rheum. 2003 Jan;48(1):166-73.

8.

Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus.

Boumpas DT, Barez S, Klippel JH, Balow JE.

Ann Intern Med. 1990 May 1;112(9):674-7.

PMID:
2334081
9.
10.

Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.

Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.

J Rheumatol. 2008 Sep;35(9):1768-75. Epub 2008 Jul 15.

PMID:
18634157
11.

Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: a case-control study.

Baba S, Katsumata Y, Kawaguchi Y, Gono T, Sugiura T, Kanno T, Hara M, Yamanaka H.

BMC Womens Health. 2011 Jun 10;11:28. doi: 10.1186/1472-6874-11-28.

12.

Outcomes of children with proliferative lupus nephritis: the role of protocol renal biopsy.

Askenazi D, Myones B, Kamdar A, Warren R, Perez M, De Guzman M, Minta A, Hicks MJ, Kale A.

Pediatr Nephrol. 2007 Jul;22(7):981-6. Epub 2007 Mar 3.

PMID:
17334789
13.

Intravenous cyclophosphamide for lupus nephritis in Thai children.

Vachvanichsanong P, Dissaneewate P, Winn T.

Scand J Rheumatol. 2004;33(5):339-42.

PMID:
15513684
14.

[Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].

Yang XY, Zhu X, Liang LQ, Zhan ZP, Ye YJ.

Zhonghua Yi Xue Za Zhi. 2005 Apr 13;85(14):960-2. Chinese.

PMID:
16061002
15.

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.

Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RW, Au TC.

Am J Med. 2006 Apr;119(4):355.e25-33.

PMID:
16564783
16.

Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus.

Borba EF, Ribeiro AC, Martin P, Costa LP, Guedes LK, Bonfá E.

J Clin Rheumatol. 2010 Apr;16(3):119-22. doi: 10.1097/RHU.0b013e3181d52ed7.

PMID:
20216330
17.

[Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].

Liang LQ, Qiu Q, Yang XY, Xu HS, Ye YJ, Zhan ZP, Lian F, Chen DY.

Zhonghua Yi Xue Za Zhi. 2008 Apr 15;88(15):1009-11. Chinese.

PMID:
18754430
18.

B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.

Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K.

Arthritis Rheum. 2005 Oct;52(10):3168-74.

19.

Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement.

Morton M, Edmonds S, Doherty AM, Dhaygude A, Helbert M, Venning M.

Rheumatol Int. 2012 Nov;32(11):3373-82. doi: 10.1007/s00296-011-2151-0. Epub 2011 Nov 2.

PMID:
22045517
20.

Supplemental Content

Support Center